Letter to the Editor in Response to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease"

Inflamm Bowel Dis. 2022 May 4;28(5):e59-e60. doi: 10.1093/ibd/izab282.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adalimumab
  • Antibodies
  • Drug Monitoring
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab
  • Tumor Necrosis Factor Inhibitors*
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab